Inex co-development deal with Enzon terminated

Guest Contributor
May 3, 2005

A development and commercialization agreement between Inex Pharmaceuticals Corp, Vancouver, and Enzon Pharmaceuticals Inc, Bridgewater NJ, has been terminated following the decision of the FDA to issue a “not approvable” letter for Inex’s leading anti-cancer drug, Marqibo. Inex received a final $5-million payment from Enzon and is seeking new investment. The collaboration with Enzon lasted little more than one year (R$, January 28/04) and its termination closely follows a dramatic downsizing of Inex’s workforce to reduce its burn rate (R$, December 21/04)….


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.